A fat-tissue-targeting clinical candidate, a first-in-class Ph. III molecule that inhibits its target by covalently modifying the target’s substrate, and a fourth-generation glucokinase activator are some examples in Drug Hunter’s May 2022 edition of Molecules of the Month.
In this month’s slide deck, you’ll find a molecule that had mitigated QTc prolongation over a prior molecule while hERG inhibition stayed constant, why reversible MAGL inhibition is being pursued, and much more, including:
- Industry context behind the molecules, target, and clinical applications
- Biological rationale for drugging the targets
- Mechanisms of action for the drugs
- Hit-finding and lead optimization strategies and tactics used
- Highlights from the binding modes and PDB codes where relevant
- Interesting aspects from the preclinical and clinical pharmacology
- Relevant patents and company history
Thanks to reviewers Ron Li, Julien Lefranc, Bryan McKibben, and Romyr Dominique for their nominations and commentary this month.